Foghorn Therapeutics Inc (FHTX)
8.92
+0.68
(+8.25%)
USD |
NASDAQ |
Nov 05, 16:00
8.92
0.00 (0.00%)
After-Hours: 18:48
Foghorn Therapeutics Enterprise Value: 170.73M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 170.73M |
| November 01, 2024 | 174.05M |
| October 31, 2024 | 136.43M |
| October 30, 2024 | 159.67M |
| October 29, 2024 | 166.86M |
| October 28, 2024 | 163.54M |
| October 25, 2024 | 141.96M |
| October 24, 2024 | 137.53M |
| October 23, 2024 | 136.43M |
| October 22, 2024 | 132.55M |
| October 21, 2024 | 114.85M |
| October 18, 2024 | 139.19M |
| October 17, 2024 | 143.07M |
| October 16, 2024 | 163.54M |
| October 15, 2024 | 137.53M |
| October 14, 2024 | 125.92M |
| October 11, 2024 | 136.98M |
| October 10, 2024 | 105.44M |
| October 09, 2024 | 116.51M |
| October 08, 2024 | 135.32M |
| October 07, 2024 | 145.28M |
| October 04, 2024 | 148.05M |
| October 03, 2024 | 128.68M |
| October 02, 2024 | 175.71M |
| October 01, 2024 | 194.52M |
| Date | Value |
|---|---|
| September 30, 2024 | 229.93M |
| September 27, 2024 | 232.70M |
| September 26, 2024 | 250.40M |
| September 25, 2024 | 221.08M |
| September 24, 2024 | 243.77M |
| September 23, 2024 | 230.49M |
| September 20, 2024 | 267.56M |
| September 19, 2024 | 249.85M |
| September 18, 2024 | 243.77M |
| September 17, 2024 | 259.26M |
| September 16, 2024 | 227.17M |
| September 13, 2024 | 252.62M |
| September 12, 2024 | 206.14M |
| September 11, 2024 | 227.72M |
| September 10, 2024 | 249.30M |
| September 09, 2024 | 233.25M |
| September 06, 2024 | 131.45M |
| September 05, 2024 | 161.88M |
| September 04, 2024 | 155.79M |
| September 03, 2024 | 149.15M |
| August 30, 2024 | 172.94M |
| August 29, 2024 | 151.37M |
| August 28, 2024 | 135.32M |
| August 27, 2024 | 154.69M |
| August 26, 2024 | 179.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-150.99M
Minimum
Mar 22 2023
891.66M
Maximum
Dec 18 2020
162.86M
Average
104.73M
Median
Apr 21 2022
Enterprise Value Benchmarks
| Sana Biotechnology Inc | 580.38M |
| Omega Therapeutics Inc | 29.25M |
| Moderna Inc | 12.09B |
| Corcept Therapeutics Inc | 4.866B |
| Akebia Therapeutics Inc | 386.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.98M |
| Revenue (Quarterly) | 6.888M |
| Total Expenses (Quarterly) | 31.12M |
| EPS Diluted (Quarterly) | -0.45 |
| Profit Margin (Quarterly) | -333.6% |
| Earnings Yield | -21.86% |
| Normalized Earnings Yield | -21.34 |